secwatch / observer
8-K filed January 14, 2025, 6:59 PM ET CIK 0000316253
regulatory confidence high sentiment negative materiality 0.80

Enzo Biochem receives NYSE non-compliance notices for low market cap & stock price

ENZO BIOCHEM INC

item 3.01item 7.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001213900-25-003421
form_type
8-K
ticker
null
cik
0000316253
company_name
ENZO BIOCHEM INC
filed_at
2025-01-14T23:59:59+00:00
discovered_at
2026-05-14T18:03:05.945987+00:00
generated_at
2026-05-28T02:27:11.891400+00:00
sec_items
["3.01", "7.01", "9.01"]
event_type
regulatory
sentiment
negative
materiality_score
0.8
calibrated_materiality_score
0.8
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001213900-25-003421
json_url
https://secwatch.observer/filing/0001213900-25-003421.json
markdown_url
https://secwatch.observer/filing/0001213900-25-003421.md
text_url
https://secwatch.observer/filing/0001213900-25-003421.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/ea022765801-8k_enzobiochem.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

1c751a1b777842073f29d328770b16ccbc6dca3a

ENZO BIOCHEM INC received a nyse deficiency notice notice regarding market value (rules 802.01B).

January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

8223b730a8264e58274e4a9f8880ad0a4f0e9336

ENZO BIOCHEM INC received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

Comparable filings

ATNM

Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

Actinium Pharmaceuticals, Inc. May 29, 2026, 5:10 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma

Comparable filing

May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately

Filing page SEC filing

CDT

CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan

CDT Equity Inc. May 28, 2026, 4:30 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma

Comparable filing

May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued listing on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s

Filing page SEC filing

CHAR

Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing

Charlton Aria Acquisition Corp May 27, 2026, 4:41 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma

Comparable filing

May 22, 2026, Charlton Aria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that

Filing page SEC filing

VSTD

Vestand receives Nasdaq delisting notice for late quarterly and annual filings

Vestand Inc. May 26, 2026, 5:18 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma

Comparable filing

May 19, 2026, the Company received a Staff Delisting Determination letter (the “Staff Determination”) from Nasdaq notifying it that Nasdaq has initiated a process which could result in the delisting of the Company’s secu

Filing page SEC filing

NVVE

Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review

Nuvve Holding Corp. May 22, 2026, 6:35 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma

Comparable filing

May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company

Filing page SEC filing

AGAE

AGAE receives Nasdaq delisting notice over bid price <$1.00 and late 10-K; will appeal

Allied Gaming & Entertainment Inc. May 11, 2026, 5:09 PM ET regulatory Items 3.01, 5.03, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma

Comparable filing

termination before an independent Hearings Panel (the “Panel”) by May 13, 2026. On November 4, 2025, Staff notified the Company that the bid price of the Common Stock had closed at less than $1.00 per share over 30 consecutive business days, and, as a result, did not comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Staff Determination was issued pursuant to Nasdaq Listing Rule 5810(c)(3)(A) on the grounds that the Company has not regained compliance with the Minimum Bid Price Rule during a 180-day compliance period and is not eligible for a second 180-day complian

Filing page SEC filing

SBEV

Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M

SPLASH BEVERAGE GROUP, INC. May 5, 2026, 7:59 PM ET regulatory Items 1.01, 1.02, 3.01, 3.02, 5.03, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma

Comparable filing

April 29, 2026, the Company received notice from NYSE Regulation (the “NYSE”) that the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined in Section 1

Filing page SEC filing

VSTD

Vestand receives Nasdaq delisting notice for late 10-K filing; may submit compliance plan by May 18, 2026

Vestand Inc. April 29, 2026, 7:59 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma

Comparable filing

April 23, 2026, Vestand Inc. (the “Company”) received a staff deficiency notice (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-K for the

Filing page SEC filing

Source: SEC EDGAR
accession 0001213900-25-003421
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.